{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antihyperglycemic+medication&page=3",
    "query": {
      "intervention": "Antihyperglycemic medication",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 151,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antihyperglycemic+medication&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antihyperglycemic+medication&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T11:23:27.468Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01620489",
      "title": "Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "liraglutide",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 279,
      "start_date": "2012-06-14",
      "completion_date": "2013-08-20",
      "has_results": true,
      "last_update_posted_date": "2019-03-19",
      "last_synced_at": "2026-10-07T11:23:27.468Z",
      "location_count": 53,
      "location_summary": "Concord, California • La Jolla, California • Los Angeles, California + 47 more",
      "locations": [
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Monterey",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01620489"
    },
    {
      "nct_id": "NCT03936010",
      "title": "Replication of the CANVAS Diabetes Trial in Healthcare Claims",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "Canagliflozin",
          "type": "DRUG"
        },
        {
          "name": "DPP-4 inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 152202,
      "start_date": "2017-09-22",
      "completion_date": "2021-02-18",
      "has_results": false,
      "last_update_posted_date": "2023-07-27",
      "last_synced_at": "2026-10-07T11:23:27.468Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03936010"
    },
    {
      "nct_id": "NCT00803920",
      "title": "Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "HealthPartners Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2006-12",
      "completion_date": "2008-02",
      "has_results": false,
      "last_update_posted_date": "2015-12-03",
      "last_synced_at": "2026-10-07T11:23:27.468Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00803920"
    },
    {
      "nct_id": "NCT01421459",
      "title": "A Study in Adults With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "LY2963016",
          "type": "DRUG"
        },
        {
          "name": "Lantus",
          "type": "DRUG"
        },
        {
          "name": "OAMs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 759,
      "start_date": "2011-09",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2014-12-18",
      "last_synced_at": "2026-10-07T11:23:27.468Z",
      "location_count": 28,
      "location_summary": "Montgomery, Alabama • Brooksville, Florida • Fort Lauderdale, Florida + 25 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "New Port Richey",
          "state": "Florida"
        },
        {
          "city": "Oviedo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01421459"
    },
    {
      "nct_id": "NCT07444203",
      "title": "Transformative Research in Diabetic Nephropathy 2.0",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetic Nephropathies",
        "Kidney Diseases",
        "Renal Insufficiency, Chronic",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Sodium-glucose cotransporter 2 inhibitors (SGLT2i)",
          "type": "DRUG"
        },
        {
          "name": "Renin-angiotensin-aldosterone system blockade",
          "type": "DRUG"
        },
        {
          "name": "Glucagon-like peptide-1 receptor agonists (GLP 1 RA)",
          "type": "DRUG"
        },
        {
          "name": "Mineralocorticoid Receptor Antagonists(MRAs)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2025-11-12",
      "completion_date": "2028-11-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-10-07T11:23:27.468Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07444203"
    },
    {
      "nct_id": "NCT05526157",
      "title": "An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Kidney Disease",
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Finerenone (Kerendia, BAY 948862)",
          "type": "DRUG"
        },
        {
          "name": "Sodium-glucose cotransporter 2 inhibitors (SGLT2i)",
          "type": "DRUG"
        },
        {
          "name": "Glucagon-like peptide-1 receptor agonists (GLP 1 RA)",
          "type": "DRUG"
        },
        {
          "name": "Steroidal mineral corticoid receptor antagonists (sMRA)",
          "type": "DRUG"
        },
        {
          "name": "Non-steroidal mineral corticoid receptor antagonists (nsMRA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50000,
      "start_date": "2022-10-01",
      "completion_date": "2024-09-05",
      "has_results": false,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-10-07T11:23:27.468Z",
      "location_count": 1,
      "location_summary": "Eden Prairie, Minnesota",
      "locations": [
        {
          "city": "Eden Prairie",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05526157"
    },
    {
      "nct_id": "NCT00194896",
      "title": "Preferred Treatment of Type 1.5 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "glyburide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "35 Years to 69 Years"
      },
      "enrollment_count": 64,
      "start_date": "2000-02",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2018-03-29",
      "last_synced_at": "2026-10-07T11:23:27.468Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00194896"
    },
    {
      "nct_id": "NCT02106364",
      "title": "A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Insulin Peglispro",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2015-02",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2016-03-28",
      "last_synced_at": "2026-10-07T11:23:27.468Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Zephyrhills, Florida • Indianapolis, Indiana + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Zephyrhills",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02106364"
    },
    {
      "nct_id": "NCT00736099",
      "title": "Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "linagliptine 5 mg",
          "type": "DRUG"
        },
        {
          "name": "linagliptine 5 mg and pioglitazone 30 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "82 Years",
        "sex": "ALL",
        "summary": "18 Years to 82 Years"
      },
      "enrollment_count": 2122,
      "start_date": "2008-08",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-06-27",
      "last_synced_at": "2026-10-07T11:23:27.468Z",
      "location_count": 13,
      "location_summary": "Chula Vista, California • Spring Valley, California • Walnut Creek, California + 10 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Northglenn",
          "state": "Colorado"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00736099"
    },
    {
      "nct_id": "NCT00528879",
      "title": "A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "77 Years",
        "sex": "ALL",
        "summary": "18 Years to 77 Years"
      },
      "enrollment_count": 915,
      "start_date": "2007-09",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2015-10-20",
      "last_synced_at": "2026-10-07T11:23:27.468Z",
      "location_count": 28,
      "location_summary": "Tempe, Arizona • Encino, California • Fresno, California + 24 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00528879"
    }
  ]
}